Clinical use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries

Trial Identifier: D8851R00001
Sponsor: AstraZeneca
NCTID:: NCT05315323
Start Date: June 2022
Primary Completion Date: June 2024
Study Completion Date: June 2024
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Saudi Arabia Riyadh, Saudi Arabia
United Arab Emirates Abu Dhabi, United Arab Emirates
United Arab Emirates Sharjah, United Arab Emirates